Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 36 results:
Author Title Type [ Year] Filters: Keyword is beta-Thalassemia [Clear All Filters]
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia..
N Engl J Med. 382(13), 1219-1231.
(2020). Beta-thalassemia: renal complications and mechanisms: a narrative review..
Hematology. 24(1), 426-438.
(2019).
(2019).
(2019). Compound Heterozygosity for Silent Cap +1570 (T>C) (HBB: c*96T>C), Codon 39 (C>T) (HBB: c.118C>T) and the Presence of ααα/αα in Greece. A Case Presentation..
Hemoglobin. 42(3), 194-195.
(2018). Deferasirox improves liver fibrosis in beta-thalassaemia major patients. A five-year longitudinal study from a single thalassaemia centre..
Br J Haematol. 181(1), 140-142.
(2018). Impact of ZBTB7A hypomethylation and expression patterns on treatment response to hydroxyurea..
Hum Genomics. 12(1), 45.
(2018). Polyneuropathy and myopathy in beta-thalassemia major patients..
Ann Hematol. 97(5), 899-904.
(2018).
(2018). Evaluation of the Greek TranQol: a novel questionnaire for measuring quality of life in transfusion-dependent thalassemia patients..
Ann Hematol. 96(11), 1937-1944.
(2017). Presence of the IVS-I-6-Mutated Allele in Beta-Thalassemia Major Patients Correlates with Extramedullary Hematopoiesis Incidence..
Acta Haematol. 137(3), 175-182.
(2017). Rivaroxaban Use in Patients with Hemoglobinopathies..
Hemoglobin. 41(3), 223-224.
(2017). Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease..
Br J Haematol. 178(1), 130-136.
(2017). A Case of Fatal Agranulocytosis That Developed in a Patient with β-Thalassemia Major Treated with Deferiprone..
Hemoglobin. 40(6), 435-437.
(2016). Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?.
Int J Hematol. 103(5), 537-44.
(2016). Evaluation of Mental Health and Physical Pain in Patients with β-Thalassemia Major in Northern Greece..
Hemoglobin. 39(3), 169-72.
(2015). Neurological complications of beta-thalassemia..
Ann Hematol. 94(8), 1261-5.
(2015). Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients..
Hemoglobin. 38(2), 111-4.
(2014). Laboratory investigation of platelet function in patients with thalassaemia..
Acta Haematol. 132(1), 45-8.
(2014). Thrombotic thrombocytopenic purpura or immune thrombocytopenia in a sickle cell/β+-thalassemia patient: a rare and challenging condition..
Transfus Apher Sci. 51(2), 175-7.
(2014). Genomic variation in the MAP3K5 gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy..
Pharmacogenomics. 14(5), 469-83.
(2013). Absence of JAK2V617F mutation in patients with beta-thalassemia major and thrombocytosis due to splenectomy..
Mol Biol Rep. 39(5), 6101-5.
(2012). KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients..
Pharmacogenomics. 13(13), 1487-500.
(2012). Restrictive pulmonary dysfunction and its predictors in young patients with β-thalassaemia major..
Pediatr Pulmonol. 47(8), 801-7.
(2012). Subclinical central nervous system involvement and thrombophilic status in young thalassemia intermedia patients of Greek origin..
Blood Coagul Fibrinolysis. 23(3), 195-202.
(2012).